Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis (MS), show the findings of the INFORMS study. The findings, which are ...
Topline results of a phase 3 trial examining the use of fingolimod (Gilenya, Novartis Pharmaceuticals) in patients with primary progressive multiple sclerosis (PPMS) show the trial missed the primary ...
Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary ...
Basel, Dec 1, 2014- Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback